Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
178.68
+0.32 (0.18%)
At close: Aug 12, 2025, 4:00 PM
178.68
0.00 (0.00%)
After-hours: Aug 12, 2025, 7:00 PM EDT
Ligand Pharmaceuticals Revenue
Quest Diagnostics had revenue of $2.76B in the quarter ending June 30, 2025, with 15.19% growth. This brings the company's revenue in the last twelve months to $10.52B, up 12.58% year-over-year. In the year 2024, Quest Diagnostics had annual revenue of $9.87B with 6.70% growth.
Revenue (ttm)
$10.52B
Revenue Growth
+12.58%
P/S Ratio
1.89
Revenue / Employee
$187,893
Employees
56,000
Market Cap
19.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.87B | 620.00M | 6.70% |
| Dec 31, 2023 | 9.25B | -631.00M | -6.38% |
| Dec 31, 2022 | 9.88B | -905.00M | -8.39% |
| Dec 31, 2021 | 10.79B | 1.35B | 14.32% |
| Dec 31, 2020 | 9.44B | 1.71B | 22.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DGX News
- 5 days ago - Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types - PRNewsWire
- 7 days ago - Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - PRNewsWire
- 14 days ago - Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - PRNewsWire
- 21 days ago - Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks - Benzinga
- 21 days ago - Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Quest Diagnostics raises annual forecasts on strong diagnostic testing demand - Reuters
- 21 days ago - Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - PRNewsWire
- 4 weeks ago - Quest Diagnostics Introduces Testing for Oropouche Virus - PRNewsWire